We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Das SRL Exhibits New Lab Solutions at MEDLAB 2017

By LabMedica International staff writers
Posted on 09 Feb 2017
Image: The AP22 IF BLOT ELITE system (Photo courtesy of Das SRL).
Image: The AP22 IF BLOT ELITE system (Photo courtesy of Das SRL).
Das SRL, which designs, manufactures, and markets analyzers and automated equipment for application in immuno-enzimatic, immuno-fluorescence, and clinical chemistry, exhibited its AP22 IF BLOT ELITE system and NEO BIL Plus bilirubinometer at MEDLAB 2017.

Italy-based Das SRL offers systems for automated ELISA process on micro-plates and immunofluorescence on slides; readers and washers for laboratories using micro-titre plates or micro-strips; programmable semi-automated photometers for clinical chemistry analysis; and neonatal bilirubinometers for bilirubin monitoring using centrifuged whole blood samples.

The company’s AP22 IF BLOT ELITE is a fully automated system for ELISA and IFA and BLOT methods. The instrument is capable of running 2 ELISA micro-plates with 8 tests on line, 16 IFA slides or 24 BLOT strips. It can perform full automation for the Dot/Western Blot, from sample dilution and dispensing, reagent dispensing, incubation, and strip washing to dot imaging processing and assessment for each strip.

Also on display at the 4-day exhibition held from February 6-9, 2017, in Dubai, UAE was Das SRL’s NEO BIL Plus, an advanced version of traditional bilirubinometers, designed to analyze the 'total bilirubin' through a microcapillary tube. NEO BIL Plus features a special reading system, which can carry out a precise sample measurement of both bilirubin and interferentials at the same point of the capillary using a small quantity of serum and without any reagents.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+

Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more